There is immense need for new intervention and prevention strategies against interstitial cystitis (IC), a chronic, relapsing, and severely debilitating disease of the urinary bladder. Estimates indicate that ~1 million cases of IC are reported annually in the United States, with 90% of these occurring in women. In a preliminary study, we showed that, along with acute phase and inflammatory cytokines, serum CXCR3 ligand levels are up-regulated in IC patients as compared with normal healthy donors. Correspondingly, we showed that CXCR3 and its ligands are up-regulated at sites of inflammation in the iliac lymph nodes and urinary bladder following experimental autoimmune cystitis (EAC) induction of chronic IC in mice. We also show that the number of CD4+ T cells, mast cells, and neutrophils is increased at systemic and mucosal sites during chronic IC in mice. Most importantly, we have demonstrated that anti-CXCL10 Abs treatment hinders the development of chronic IC. Urinary bladder CD4+ T cells, mast cells, neutrophil infiltrates, local production of CXCR3 ligand, and systemic Th1 cytokines were also reduced following anti-CXCL10 Abs treatment in mice after chronic IC. These results provide a strong rationale for our central hypothesis, which is to determine whether differential expression of CXCR3 and CXCR3 ligands by hematopoietic, myeloid, and non-hematopoietic cells mediates the induction and progression of IC. Targeting CXCR3 and its ligands may serve as a potential therapeutic option for IC.
Three specific aims will be used to elucidate the precise role of CXCR3 and CXCR3 ligand during IC progression.

Public Health Relevance

We will test the hypothesis that differential expression of CXCR3 and CXCR3 ligand by hematopoietic, myeloid, and non-hematopoietic cells are essential for the induction and progression of interstitial cystitis (IC), targeting CXCR3 and its ligands may serve as a potential therapeutic option for IC. The proposal is innovative and will provide novel information on immune mechanism underlying CXCR3 ligand-mediated amelioration of IC.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56DK087836-01A1
Application #
8537713
Study Section
Special Emphasis Panel (UGPP)
Program Officer
Bavendam, Tamara G
Project Start
2012-09-15
Project End
2014-08-31
Budget Start
2012-09-15
Budget End
2014-08-31
Support Year
1
Fiscal Year
2012
Total Cost
$123,300
Indirect Cost
$33,300
Name
University of South Carolina at Columbia
Department
Pathology
Type
Schools of Medicine
DUNS #
041387846
City
Columbia
State
SC
Country
United States
Zip Code
29208
Shamran, Haidar; Singh, Narendra P; Zumbrun, Elizabeth E et al. (2017) Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation. Brain Behav Immun 59:10-20
Singh, Udai P; Singh, Narendra P; Murphy, E Angela et al. (2016) Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine 77:44-9
Singh, Udai P; Singh, Narendra P; Guan, Hongbing et al. (2014) The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease. Int Rev Immunol 33:23-33
Singh, Udai P; Murphy, Angela E; Enos, Reilly T et al. (2014) miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses. Immunology 143:478-89
Singh, Udai P; Singh, Narendra P; Guan, Hongbing et al. (2013) Leptin antagonist ameliorates chronic colitis in IL-10?/? mice. Immunobiology 218:1439-51
Guffey, Catherine R; Fan, Daping; Singh, Udai P et al. (2013) Linking obesity to colorectal cancer: recent insights into plausible biological mechanisms. Curr Opin Clin Nutr Metab Care 16:595-600
Singh, Udai P; Singh, Narendra P; Guan, Honbing et al. (2013) The severity of experimental autoimmune cystitis can be ameliorated by anti-CXCL10 Ab treatment. PLoS One 8:e79751